A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting 120 enrolled CRISPR Therapeutics AG

NaSequentialOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

Timeline

Start: 2023-03-10
Primary completion: 2030-01
Completion: 2030-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTX112	Cell therapy	—	Intravenous

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Summary

Timeline

Drugs

Indications